Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatme…
Biotechnology
US, La Jolla [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Longboard Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -2.5100 | -2.403 | 0 | 0 | -43 | -54 | -44 | 0 | -44 | 0 | 10 | 0 |
| 2024 | -2.3900 | -2.226 | 0 | 3 | -54 | -49 | -56 | 0 | -56 | 0 | 13 | 0 |
| 2025 | - | -2.824 | - | 2 | - | -64 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F31/td> | - | 2.F31 | - | 2.F31 |
| 2027 | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2028 | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |